Table 1 Patient characteristics
Variable | Overall population, no: 253 | Secondary prevention, no: 190 | Primary prevention, no: 63 | P value |
|---|---|---|---|---|
Age, mean (SD) years | 50.2 (14.7) | 51.5 (14.5) | 46.5 (14.8) | 0.019 |
Male gender, No (%) | 175 (69.2) | 131 (68.9) | 44 (69.8) | 0.894 |
Systemic hypertension, No (%) | 124 (49.0) | 94 (49.5) | 30 (47.6) | 0.913 |
Diabetes mellitus, No (%) | 51 (20.2) | 40 (21.2) | 11 (18.0) | 0.730 |
Dyslipidemia, No (%) | 45 (17.8) | 36 (19.0) | 9 (14.8) | 0.571 |
Chronic Obstructive Pulmonary Disease | 9 (3.6) | 6 (3.2) | 3 (4.9) | 0.816 |
Ischemic Heart Disease | 99 (39.1) | 84 (44.4) | 15 (24.6) | 0.009 |
Atrial fibrillation/atrial flutter | 22 (8.7) | 18 (9.5) | 4 (6.3) | 0.614 |
LVEDd, mean (SD) (mm) | 58.7 (13.2) | 55.8 (11.6) | 67.3 (14.1)) | < 0.0001 |
LVESd, mean (SD) (mm) | 47.5 (16.2) | 44.1 (13.8) | 55.5 (18.7) | < 0.0001 |
Ejection Fraction, mean (SD) % | 36.6 (19.5) | 39.8 (18.3) | 27.5 (20.2) | < 0.0001 |
NYHA Functional Class Ι/ΙΙ, No (%) | 188 (74.3) | 154 (81.1) | 34 (54.0) | < 0.0001 |
NYHA Functional Class ΙΙΙ/ΙV, No (%) | 65 (25.7) | 36 (18.9) | 29 (46.0) | < 0.001 |
Statin | 120 (47.4) | 96 (50.8) | 24 (38.1) | 0.109 |
Beta blocker, No (%) | 216 (85.4) | 158 (83.6) | 58 (92.1) | 0.146 |
NDP CCB, No (%) | 5 (2.0) | 3 (1.6) | 2 (3.2) | 0.799 |
Amiodarone, No (%) | 83 (32.8) | 77 (41.0) | 6 (9.5) | < 0.0001 |
Sotalol, No (%) | 6 (2.4) | 5 (2.7) | 1 (1.6) | 0.995 |
ACE-inhibitor/ ARB, No (%) | 176 (69.6) | 123 (65.1) | 53 (84.1) | 0.007 |
Warfarin, No (%) | 52 (20.6) | 35 (18.5) | 17 (27.0) | 0.159 |